<DOC>
	<DOCNO>NCT01730547</DOCNO>
	<brief_summary>The aim study evaluate safety efficacy autologous mesenchymal stromal cell treatment Multiple Sclerosis .</brief_summary>
	<brief_title>Mesenchymal Stem Cells Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>1 . Diagnosis MS a. Relapsing remit MS ( RRMS ) respond least year attempt therapy one approved therapy ( betainterferon , glatiramer acetate , natalizumab , mitoxantrone , fingolimod ) evidence one following : . ≥1 clinically document relapse past 12 month ii . ≥2 clinically document relapse last 24 month iii . ≥1 GEL MRI perform within last 12 month b . Secondary progressive MS ( SPMS ) respond least year attempt therapy one approved therapy ( betainterferon , glatiramer acetate , natalizumab , mitoxantrone , fingolimod ) evidence : i. increase ≥1 EDSS point ( randomization EDSS ≤ 5.0 ) 0.5 EDSS point ( randomization EDSS ≥ 5.5 ) last 12 month ii . ≥1 clinically document relapse ≥ 1 GEL MRI within last twelve month . c. Primary progressive MS ( PPMS ) patient follow feature : i. increase ≥1 EDSS point ( randomization EDSS ≤ 5.0 ) 0.5 EDSS point ( randomization EDSS ≥5.5 ) , last twelve month ii . ≥ 1 GEL MRI perform within last 12 month iii . positive cerebrospinal fluid ( CSF ) ( oligoclonal banding ) 2 . Age 18 50 year 3 . Disease duration 2 10 year ( include ) 4 . EDSS 3.0 6.5 1 . RRMS fulfil inclusion criterion 2 . SPMS fulfil inclusion criterion 3 . PPMS fulfil inclusion criterion 4 . Any active chronic infection include infection HIV12 chronic Hepatitis B Hepatitis C 5 . Treatment immunosuppressive therapy , include natalizumab fingolimod , within 3 month prior randomization 6 . Treatment interferonbeta glatiramer acetate within 30 day prior randomization 7 . Treatment corticosteroid within 30 day prior randomization 8 . Relapse occur 60 day prior randomization 9 . Previous history malignancy basal cell carcinoma skin carcinoma situ remission one year 10 . Severely limited life expectancy another comorbid illness 11 . History previous diagnosis myelodysplasia previous hematologic disease current clinically relevant abnormality white blood cell count 12 . Pregnancy risk pregnancy ( include patient unwilling practice active contraception duration study ) 13. eGFR &lt; 60 mL/min/1.73m2 know renal failure inability undergo MRI examination . 14 . Inability give write informed consent accordance research ethic board guideline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Autoimmune disease</keyword>
</DOC>